apremilast / Generic mfg. - LARVOL DELTA

Marked Improvement of Palmoplantar Pustulosis After the Reintroduction of Apremilast Following Initiation of Dental Infection Control and Periodontal Therapy. (PubMed, Cureus) - "This single case provides a hypothesis-generating observation that reduction in periodontal inflammatory burden was temporally associated with partial improvement before apremilast reintroduction, after which further marked improvement was observed. Evaluation and management of oral infectious foci and periodontal inflammation may therefore be considered an adjunctive strategy in selected patients with PPP who have a suboptimal response to systemic therapy, particularly when clinically or radiographically evident oral disease is present."

Journal • Dental Disorders • Dermatology • Immunology • Infectious Disease • Inflammation • Periodontitis • Psoriasis • Urticaria

Microbiome Beta-Glucuronidase Activity Does Not Limit Bioconversion or Pharmacokinetic Consistency of the Colon-Targeted PDE4 Prodrug PALI-2108 in Ulcerative Colitis (ACG 2026) - "In UC subjects, trough-region geometric CVs (~40â57%) compared favorably with apremilast variability metrics (NDA FDA)... Bioconversion of oral PALI-2108 to active PALI-0008 was found in HVs and UC subjects (Fig. 1). Baseline bacterial species and MetaCyc pathway alpha/beta diversity analyses were similar between groups."

PK/PD data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

An Atypical Presentation of Intestinal Behçetâs Disease (ACG 2026) - "Case Description/ A 36-year-old male with BD on azathioprine, apremilast, and prednisone presented to clinic for evaluation of episodic nausea, non-bloody diarrhea, early satiety and fecal urgency. This case also highlights that microscopic inflammatory colitis may occur even in the absence of overt mucosal ulceration. Recognition of atypical gastrointestinal manifestations of BD is essential, as treatment escalation may be required to prevent progressive intestinal involvement and improve quality of life."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ophthalmology • Rare Diseases • Ulcerative Colitis • Vasculitis

PALI-2108, a Next-Generation Oral PDE4 Inhibitor Prodrug, Demonstrates Localized Ileocolonic Exposure With Favorable Tolerability in IBD (ACG 2026) - "PK was consistent with delayed enteric release followed by localized ileocolonic bioactivation to PALI-0008, with delayed Tmax and prolonged exposure. Sustained colonic tissue concentrations were achieved while systemic Cmax remained attenuated. In FSCD patients, PK demonstrated favorable steady-state tissue:plasma ratios (Fig."

Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • CRP

Hidradenitis Suppurativa from Preconception to Lactation: Clinical Treatment Decision-Making Review. (PubMed, Dermatol Ther (Heidelb)) - "Topical clindamycin, benzoyl peroxide, chlorhexidine, and selected beta-lactam antibiotics appear to represent preferred options for mild disease or acute flares, whereas tetracyclines, retinoids, spironolactone, apremilast, Janus kinase inhibitors, and most glucagon-like peptide-1 (GLP-1) receptor agonists require avoidance or discontinuation because of fetal or neonatal safety concerns. Among biologics, tumor necrosis factor-α inhibitors remain the best-characterized agents, with certolizumab pegol offering minimal placental transfer and adalimumab or infliximab requiring individualized decisions regarding continuation and timing of discontinuation. Evidence for newer agents, including secukinumab and bimekizumab, is evolving but remains more limited. The review also highlights the importance of preconception counseling, medication transition, multidisciplinary delivery planning, postpartum flare prevention, breastfeeding-compatible therapy, and individualized..."

Journal • Review • Dermatology • Hidradenitis Suppurativa • Immunology • Oncology • Women's Health

A sustainable and green MSPE-HPLC-DAD method for trace analysis of apremilast using new TMMS/decanoic acid-modified magnetic sorbents. (PubMed, Anal Methods) - "The results demonstrate that this functionalized magnetic sorbent offers a high-capacity, cost-effective, and highly reproducible alternative for the routine monitoring of apremilast in complex matrices. The overall method performance and eco-friendliness were quantitatively validated using AMRI (70), AGREE (0.70), AGREEprep (0.63), and SAMI (26) metrics, establishing the procedure as a reliable and sustainable analytical tool."

Journal

Positive Allosteric GABAA Receptor Modulators Reduce Ethanol Consumption and Acute Functional Tolerance. (PubMed, Alcohol) - "We tested four such modulators (loreclezole, etifoxine, topiramate, and compound 2-261) on voluntary ethanol drinking and related behaviors in mice. Like apremilast, all four compounds dose-dependently prolonged recovery from ethanol-induced ataxia, prevented the development of acute tolerance, and reduced two-bottle choice ethanol consumption without altering blood ethanol clearance. Thus, both indirect activation of β3-containing GABAA receptors by apremilast and direct activation by positive allosteric modulators with selectivity for β2/β3-containing receptors reduce ethanol drinking while preventing acute tolerance."

Journal • Ataxia • Movement Disorders

Efficacy of Apremilast on Fingernail Bed Inflammation in Patients With Psoriatic Arthritis: Dynamic Contrast-Enhanced MRI Results From the Phase 4 MOSAIC Study (ACR Convergence 2026) - No abstract available

Clinical • P4 data • Immunology • Inflammation • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Risk Factor Clusters Associated With Progression From Oligoarticular to Polyarticular Psoriatic Arthritis: Apremilast Treatment Effect in the FOREMOST Study (ACR Convergence 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Efficacy of Apremilast in Patients with Early Psoriatic Arthritis: A Post Hoc Pooled Analysis of Seven Clinical Trials (ACR Convergence 2026) - No abstract available

Retrospective data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Flip-flop phenomenon - from iksekizumab to dupilumab with apremilast. (EADV 2026) - No abstract available

Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

Refractory Epidermolysis Bullosa Acquisita Treated With Apremilast. (PubMed, J Dermatol) - No abstract available

Journal

Assessment of the effectiveness of apremilast in the treatment of nail psoriasis employing Nail Area Psoriasis Severity Index (NAPSI), and Dermatologic Life Quality Index (DLQI: an observational cross-sectional study. (EADV 2026) - No abstract available

Observational data • Dermatology • Immunology • Psoriasis

Real-world data assessing the efficacy and tolerability of deucravacitinib and apremilast: A retrospective, single-centre observational study (EADV 2026) - No abstract available

Observational data • Real-world • Real-world evidence • Retrospective data • Dermatology • Dermatopathology • Immunology • Psoriasis

Refractory Palmoplantar Psoriasis Successfully Treated With Apremilast After Failure of Multiple Systemic and Biologic Therapies – A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatology • Immunology • Psoriasis

safety and efficacy of apremilast in the treatment of moderate to severe plaque psoriasis (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Real-World Effectiveness, Drug Survival and Laboratory Changes in Patients with Plaque Psoriasis Treated with Apremilast (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Risk Factor Clusters Associated With Progression From Oligoarticular to Polyarticular Psoriatic Arthritis: Apremilast Treatment Effect in the FOREMOST Study (EADV 2026) - No abstract available

Clinical • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

safety and efficacy of apremilast in the treatment of moderate to severe plaque psoriasis (EADV 2026) - No abstract available

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Comparison of the side effect profiles of weekly versus daily dose escalation regimen of Apremilast: An open-label randomized controlled trial (EADV 2026) - No abstract available

Adverse events • Clinical

Apremilast for severe and refractory subcorneal pustular dermatosis (EADV 2026) - No abstract available

Dermatology

Efficacy of Apremilast in Patients with Moderate Psoriasis, Including High-impact Site Involvement: A Pooled Analysis of Six Trials (EADV 2026) - No abstract available

Retrospective data • Dermatology • Immunology • Psoriasis

Navigating Treatments in Folliculitis Decalvans: A Comprehensive Systematic Review. (PubMed, J Dtsch Dermatol Ges) - "Antibiotic-based therapies, particularly rifampicin-clindamycin combinations, showed favorable initial responses but frequent relapse after discontinuation. Isotretinoin demonstrated comparatively durable responses, with remission rates up to 82%. Biologic and targeted immunomodulatory therapies, including TNF-α inhibitors, apremilast, and various JAK inhibitors, showed promising outcomes in refractory cases. Current evidence supports individualized long-term treatment strategies focused on inflammation control and prevention of irreversible scarring."

Journal • Review • Alopecia • Immunology • Inflammation

Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data. (PubMed, Br J Dermatol) - "In this large cohort study, tuberculosis and meningitis were rare and longer-term follow-up is required to further characterise the risk with newer treatments. Candidiasis and fungal infections were more common with increased risks among patients receiving IL-17 inhibitors."

Journal • Candidiasis • CNS Disorders • Dermatology • Immunology • Infectious Disease • Psoriasis • Pulmonary Disease • Respiratory Diseases • Tuberculosis • IL12A • IL17A

Comments on "Efficacy and safety of different doses of apremilast in mild to moderate psoriasis". (PubMed, Indian J Pharmacol) - No abstract available

Journal • Dermatology • Immunology • Psoriasis